Clinical Trial Detail

NCT ID NCT02725268
Title Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors Millennium Pharmaceuticals, Inc.
Indications

endometrial carcinoma

Therapies

Paclitaxel

Sapanisertib

MLN1117 + Sapanisertib

Age Groups: adult

No variant requirements are available.